The Senolytic Protocol: Clearing Zombie Cells for Longer Healthspan

Of the 12 hallmarks of aging — see our hallmarks of aging guide for the full framework — cellular senescence may be the most directly actionable. Senescent cells are cells that have stopped dividing but refuse to die. They accumulate with age, secrete a toxic cocktail of inflammatory molecules called the senescence-associated secretory phenotype (SASP), and drive much of the chronic inflammation (inflammaging) that underlies cardiovascular disease, neurodegeneration, cancer, and frailty. They have earned the popular nickname "zombie cells."

Senolytic protocols aim to selectively clear these cells. The field was launched in 2015 by a Mayo Clinic team led by Jim Kirkland, who showed that a combination of dasatinib (a leukemia drug) and quercetin (a plant flavonoid) selectively killed senescent cells in mice and extended healthspan. A decade later, the field has moved into human trials for conditions including diabetic kidney disease, idiopathic pulmonary fibrosis, Alzheimer's disease, and frailty — with mixed but interesting results. This guide covers the science, the protocols, how to measure effectiveness, and the supplements worth knowing. For a forward-looking view of the broader senolytic field, see our Longevity Trends 2026 report.

What senescent cells are and why they accumulate

Cellular senescence is a state in which a cell has permanently exited the cell cycle in response to stress. The triggers are diverse: telomere shortening (replicative senescence), DNA damage (radiation, chemotherapy, oxidative stress), oncogene activation (cells become senescent rather than cancerous as a tumor-suppressive mechanism), mitochondrial dysfunction, and epigenetic drift. Once a cell becomes senescent, it stops dividing but stays metabolically active — and that metabolic activity is the problem.

In a young, healthy body, senescent cells are cleared by the immune system (NK cells, macrophages) within days to weeks. With age, two things go wrong: the rate of senescent cell generation increases (more DNA damage, mitochondrial dysfunction, etc.), and the immune system's ability to clear them declines (immunosenescence). The result is a steady accumulation of senescent cells in tissues throughout the body. By age 80, some tissues may have 10× more senescent cells than at age 30.

Senescent cells accumulate preferentially in adipose tissue, the kidney, the vasculature, the brain, and the bone marrow. This tissue distribution helps explain why these are the organs that fail most often with age.

The SASP: how zombie cells poison their neighbors

The defining pathogenic feature of senescent cells is the senescence-associated secretory phenotype (SASP) — a coordinated secretion of inflammatory cytokines (IL-6, IL-1α, IL-8), chemokines, growth factors, and matrix-remodeling enzymes. The SASP is not random: it is a stereotyped secretory program driven by NF-κB and p38 MAPK signaling.

The SASP causes three categories of damage:

• Paracrine senescence: SASP factors induce senescence in neighboring cells. One senescent cell can convert multiple nearby cells to senescence — this is why a small number of senescent cells can have outsized tissue-level effects.
• Chronic inflammation (inflammaging): SASP cytokines drive the low-grade, chronic inflammation that underlies most age-related disease. Older adults have elevated IL-6, CRP, and other inflammatory markers — much of this traces to senescent cells.
• Tissue dysfunction: SASP factors disrupt tissue architecture, impair stem cell function, and alter the extracellular matrix. In adipose tissue, SASP drives insulin resistance. In bone, it drives osteoporosis. In the brain, it drives neuroinflammation and cognitive decline.

This is why clearing senescent cells — even a modest fraction of them — can have outsized tissue-level benefits. The Mayo Clinic mouse studies showed that clearing senescent cells in old mice extended median lifespan by ~25% and dramatically improved physical function, without changing maximum lifespan. The translation to humans is what the current trials are testing.

Evidence in animals and humans

Animal evidence is robust. Genetic clearance of senescent cells (using transgenic "INK-ATTAC" mice) extends median lifespan by ~25%. Pharmacological clearance with dasatinib + quercetin or fisetin restores physical function in old mice, improves cardiovascular function in atherosclerosis models, and reduces neuroinflammation in Alzheimer's models.

Human evidence is more limited but growing:

• Diabetic kidney disease: A 2020 Mayo Clinic trial showed that 3 days of dasatinib + quercetin reduced senescent cell markers in adipose tissue of diabetic kidney disease patients at 11 days, with maintained improvements in physical function at 30 days.
• Idiopathic pulmonary fibrosis (IPF): A 2019 trial showed that dasatinib + quercetin improved physical function (4-minute walk distance, chair-stand test) in IPF patients over 3 weeks.
• Alzheimer's disease: The SToMP-AD trial is testing senolytic combinations in early Alzheimer's disease, with results expected in 2026–2027.
• Frailty and aging: Several trials are testing senolytic protocols in older adults with frailty, looking at physical function and biomarkers.

The human data is suggestive but not yet definitive. Effect sizes have been modest, and the field is still working out dosing, frequency, and which patient populations benefit most. The excitement in 2026 is that we have moved from "does this work in mice?" to "which humans does this work for?" — that is real scientific progress.

The Mayo Clinic dasatinib + quercetin protocol

The original Kirkland lab protocol uses dasatinib (a chemotherapy drug approved for chronic myeloid leukemia) combined with quercetin (a flavonoid found in onions, apples, and capers). Dasatinib targets senescent adipocyte progenitors; quercetin targets senescent endothelial cells. The combination was designed to address the heterogeneity of senescent cell populations — different senolytic compounds kill different senescent cell subtypes.

The standard D+Q protocol:

• Dasatinib: 100 mg/day orally
• Quercetin: 1,000 mg/day orally (often as phytosome form for bioavailability)
• Schedule: 2 consecutive days, repeated monthly (the "hit-and-run" pattern)
• Duration of trial: Typically 3 monthly cycles before evaluating

Important cautions: Dasatinib is a prescription chemotherapy drug with significant side effects (cytopenias, fluid retention, pleural effusions, increased infection risk). It should not be used outside of a clinical trial or without physician supervision. The combination is being studied under FDA-approved investigational protocols. We do not recommend self-administration.

For people who cannot access a clinical trial or who prefer a non-prescription approach, the natural alternative is fisetin — see the next section.

Fisetin as the natural alternative

Fisetin is a flavonoid found in strawberries, apples, persimmons, onions, and cucumbers. In 2018, Paul Robbins and Laura Niedernhofer at the University of Minnesota screened 10 flavonoids for senolytic activity and found that fisetin was the most potent — outperforming quercetin in cell-culture assays and reducing senescent cell burden in old mice when administered intermittently. The Mayo Clinic has since incorporated fisetin into senolytic clinical trials.

A reasonable fisetin protocol (based on ongoing human trials):

• Dose: 1,000–1,500 mg/day (often dosed at 20 mg/kg, which works out to 1,200–1,500 mg for a 60–75 kg adult)
• Form: Fisetin extract standardized to >50% purity
• Schedule: 2 consecutive days per month (the "hit-and-run" pattern)
• Duration of trial: 3–6 monthly cycles before evaluating biomarkers

Unlike dasatinib, fisetin has an excellent safety profile. Phase 1 trials have used up to 20 mg/kg/day for 2 days with no significant adverse events. The main theoretical concerns are bone marrow suppression (senolytics may also clear desirable cells including hematopoietic stem cells) and liver metabolism load — hence the recommendation to cycle rather than take daily. Our fisetin supplements guide covers the product options in detail.

For the quercetin half of the natural stack: Quercetin is widely available over the counter and pairs well with fisetin for broader senescent cell subtype coverage. Our quercetin supplements guide covers sourcing and form. The combination of fisetin + quercetin during the 2-day monthly senolytic "pulse" is the most evidence-backed over-the-counter approach.

Periodic "hit-and-run" dosing: why intermittent, not daily

The defining pharmacological insight of the senolytic field is that these compounds should be taken intermittently, not daily. The reasoning:

• Senescent cells are not rapidly replaced. Once cleared, it takes weeks for the senescent cell pool to re-accumulate. Daily dosing provides no additional senolytic benefit but increases side-effect burden.
• Senolytics are cytotoxic by design. They kill cells. Daily administration risks off-target killing of desirable cells (stem cells, hematopoietic precursors). The 2-day pulse minimizes this risk.
• Cost and tolerability. High-dose fisetin is expensive. Daily use at senolytic doses would cost $300–500/month. Monthly use costs $30–50/month.
• Recovery period. The 28-day off-period allows the immune system to clear debris and the bone marrow to repopulate.

The "2 days on, 28 days off" pattern has become the standard in both clinical trials and over-the-counter protocols. Some practitioners vary this — 3 days on, 4 weeks off; 5 days on, 8 weeks off — but the 2-day monthly pattern is the most-studied and easiest to adhere to.

How to measure effectiveness

Measuring whether a senolytic protocol is "working" is harder than taking it. The gold standard is tissue biopsy for senescent cell markers (p16INK4a, p21CIP1), but this is invasive and not practical for routine use. Practical alternatives:

• Blood inflammatory markers: hs-CRP, IL-6, TNF-α. These should trend down over 3–6 monthly cycles if the protocol is clearing SASP-producing cells. A baseline measurement before starting and a 3-month measurement is reasonable.
• Blood cell counts: A CBC with differential before, during, and after the first cycle. Watch for cytopenias. If platelets or white cells drop significantly, the protocol may be too aggressive.
• Physical function: Grip strength, gait speed, 6-minute walk distance, chair-stand time. These are the function outcomes used in clinical trials and can be tracked at home with simple tools.
• Subjective measures: Energy, sleep quality, joint stiffness, cognitive clarity. These are noisy but useful for individual tracking.
• Biological age tests: Epigenetic clocks (Horvath, GrimAge, PhenoAge) may shift with sustained senolytic use, though the effect size is unknown. Our biological age tests guide covers options, and our guide to lowering biological age covers the broader framework.

The honest answer is that for most people in 2026, you cannot definitively know whether your senolytic protocol is "working" at the cellular level. You can track biomarker and functional trends over 6–12 months and make a reasonable judgment about whether to continue.

Supporting the protocol: liver, gut, inflammation

Senolytics are metabolized by the liver, and the dying cells they create must be cleared by the immune system. Supporting this clearance reduces side effects and may improve effectiveness:

• Liver support: TUDCA (tauroursodeoxycholic acid) supports bile flow and reduces ER stress on hepatocytes during the senolytic pulse. 250–500 mg/day during the 2-day pulse and for 3 days after. Our TUDCA supplements guide covers options.
• NAC for glutathione support: N-acetyl cysteine (600 mg/day) supports glutathione synthesis, which the liver uses to clear senolytic-induced cellular debris. See our NAC guide.
• Spermidine for autophagy support: Spermidine induces autophagy, which helps the body clear cellular debris from senolytic activity. 1–3 mg/day, taken continuously. Our spermidine guide covers options.
• Hydration and electrolytes: Cellular debris clearance requires adequate hydration. Mineral/electrolyte intake (sodium, potassium, magnesium) during the pulse helps. Our electrolyte supplements guide covers options.
• Liposomal vitamin C: High-dose vitamin C during the pulse may support the oxidative clearance of dying cells. Our glutathione guide covers the broader antioxidant picture.

This supportive stack is not mandatory, but it is reasonable for people taking the fisetin/quercetin protocol seriously. The principle is that senolytics create cellular debris that must be cleared; you want your clearance machinery (liver, immune system, autophagy) operating at its best during the pulse.

Recommended products for the senolytic protocol

The products below cover the core senolytic pulse and the supporting stack for cellular debris clearance during and after the 2-day monthly cycle.

The senolytic pulse (2 consecutive days/month):

Continuous autophagy support (taken daily, year-round):

Liver and antioxidant support during the pulse (days 1–5 each month):

The bottom line

Senolytic protocols are one of the most intellectually compelling interventions in the longevity field. The mechanism is well-established, the animal data is strong, and the human data — while still early — is moving in the right direction. For most adults over 50, particularly those with elevated inflammatory markers or signs of accelerated aging, a monthly fisetin + quercetin "hit-and-run" pulse is a reasonable, low-risk intervention.

The prescription dasatinib + quercetin protocol is more potent but requires physician supervision and is best pursued through clinical trial enrollment. For people interested in the broader senolytic pipeline — including small molecules from Unity Biotechnology, Rubedo Life Sciences, and other companies in clinical development — see our Longevity Trends 2026 report. For the full framework of aging biology, see our hallmarks of aging guide. For practical implementation, the how to lower your biological age guide and the complete guides hub cover the broader landscape.